Characterisation of prostate cancer sialome re-engineering via CMAH transfection reveals a bystander effect that propagates Neu5Gc presentation to neighbouring cells
Yumiko UnoiD, Amanda R. NobleiD, Esme HuttoniD, Nathalie Yvonne Micheline SignoretiD, Martin A. FascioneiD
Abstract
Sialic acids are a family of nine-carbon -keto sugars that play essential roles in human health and disease. In mammals, they are found in two main forms: N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), with interactions between Neu5Ac-containing glycans and Siglec receptors on immune cells increasingly recognised as glyco-immune checkpoints, promoting immunosuppression. However, humans do not synthesise Neu5Gc due pseudogenisation of the CMAH gene which encodes the cytidine monophospho-N-acetylneuraminic acid hydroxylase enzyme responsible for CMP-Neu5Ac conversion into CMP-Neu5Gc, which then serves as the donor substrate for sialyltransferases. Here, we investigated the effects of re-engineering tumour cell-surface glycans in a prostate cancer cell model by expressing rat CMAH, thereby enabling the conversion of CMP-Neu5Ac to CMP-Neu5Gc. LNCaP cells transfected with the rat CMAH gene predominantly incorporated Neu5Gc into mucin-associated O-glycans implicated in immune suppression. Treatment with sialidase significantly reduced Neu5Gc expression, indicating that Neu5Gc was presented on cell-surface glycans, while cell-tracing experiments demonstrated the transfer of Neu5Gc to neighbouring cells, revealing a potential bystander effect capable of propagating Neu5Gc expression within the tumour microenvironment.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Profiling Siglec-7 and Siglec-9 ligands across the LuCaP PDX series: Implications for glyco-immune checkpoint inhibition in advanced prostate cancer
Ziqian Peng, Libby Blencoe, … Jennifer Munkley·bioRxiv·Oct 19, 2026
- The Androgen Receptor and MYC synergise to modulate the synthesis of Siglec-7 ligands in prostate cancer
Adam Duxfield, Rebecca Garnham, … Emma Scott·bioRxiv·Oct 15, 2025
- Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis
Ziqian Peng, Kirsty Hodgson, … Jennifer Munkley·bioRxiv·Nov 12, 2025
- ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer
R. Garnham, D. Geh, … E. Scott·bioRxiv·Apr 3, 2023
- Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2
R. Wieboldt, E. Carlini, … N. Rodrigues Mantuano·bioRxiv·Jun 29, 2023
- Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade
M. A. Stanczak, N. R. Mantuano, … H. Laeubli·Science Translational MedicinePeer-reviewed·Nov 2, 2022